Pharmacelera has closed a €6 million financing round to accelerate its growth in the United States and further develop its high speed, high accuracy drug discovery platform. The funding round was led by Heran Partners and included participation from Clave Capital, Inveready and Bio&Tech Smart Capital. The investment will support the establishment of a permanent U.S. team and deepen relationships with major pharmaceutical and biotech customers on both coasts. Pharmacelera applies proprietary algorithms that combine Quantum Mechanics and Artificial Intelligence to explore vast chemical “exaSpace” and identify novel molecular candidates with much greater speed and efficiency than traditional approaches.

This technology can be applied across all stages of drug discovery from initial hit finding through to lead optimisation. The company, headquartered in Barcelona, has already contributed to over 100 projects with global pharma and biotech partners and will use the funding to expand technical capabilities of its platform while strengthening its U.S. presence. Leaders of the company say the backing validates their deep tech approach and positions Pharmacelera to better support partners in identifying diverse, high-quality candidates for therapeutic development.